Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy
Febrile Infection-Related Epilepsy Syndrome (FIRES) is a unique catastrophic epilepsy syndrome, and the development of drug-resistant epilepsy (DRE) is inevitable. Recently, anakinra, an interleukin-1 receptor antagonist (IL-1RA), has been increasingly used to treat DRE due to its potent anticonvuls...
Main Authors: | Gaku Yamanaka, Yu Ishida, Kanako Kanou, Shinji Suzuki, Yusuke Watanabe, Tomoko Takamatsu, Shinichiro Morichi, Soken Go, Shingo Oana, Takashi Yamazaki, Hisashi Kawashima |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/12/6282 |
Similar Items
-
Role of Neuroinflammation and Blood-Brain Barrier Permutability on Migraine
by: Gaku Yamanaka, et al.
Published: (2021-08-01) -
Application of anakinra in inflammatory dermatoses
by: Xiaomei YOU, et al.
Published: (2024-01-01) -
The Beneficial Outcome of Subsequent Treatment with Anakinra during the Chronic Phase of Febrile Infection-Related Epilepsy Syndrome (FIRES): A Case Report
by: Tina Luize Cupane, et al.
Published: (2023-12-01) -
The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation
by: Max Hübner, et al.
Published: (2020-02-01) -
Use of anakinra in severe COVID-19: A case report
by: Giovanni Filocamo, et al.
Published: (2020-07-01)